Omeros CorpNASDAQ:OMER
- LAST PRICE3.2100
- TODAY'S CHANGE (%)-0.1300 (-3.8922%)
- Bid / Lots2.9200/ 10
- Ask / Lots4.0000/ 4
- Open / Previous Close3.3200 / 3.3400
- Day Range
- 52 Week Range
- Volume429,230
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OMER |
|---|---|---|
| 09:32 ET | 2081 | 3.3598 |
| 09:38 ET | 17699 | 3.29 |
| 09:39 ET | 3606 | 3.29 |
| 09:41 ET | 1700 | 3.27 |
| 09:43 ET | 2218 | 3.245 |
| 09:45 ET | 1900 | 3.27 |
| 09:48 ET | 2500 | 3.27 |
| 09:50 ET | 2055 | 3.275 |
| 09:52 ET | 5100 | 3.29 |
| 09:54 ET | 1100 | 3.2773 |
| 09:56 ET | 400 | 3.3 |
| 09:57 ET | 1607 | 3.33 |
| 09:59 ET | 401 | 3.32 |
| 10:01 ET | 100 | 3.33 |
| 10:03 ET | 1403 | 3.32 |
| 10:06 ET | 1600 | 3.33 |
| 10:08 ET | 1603 | 3.32 |
| 10:10 ET | 700 | 3.33 |
| 10:14 ET | 600 | 3.355 |
| 10:15 ET | 1281 | 3.365 |
| 10:17 ET | 952 | 3.35 |
| 10:19 ET | 100 | 3.35 |
| 10:21 ET | 600 | 3.35 |
| 10:24 ET | 700 | 3.354 |
| 10:26 ET | 874 | 3.35 |
| 10:28 ET | 160 | 3.37 |
| 10:32 ET | 744 | 3.38 |
| 10:33 ET | 2293 | 3.3639 |
| 10:35 ET | 400 | 3.38 |
| 10:37 ET | 1000 | 3.3701 |
| 10:39 ET | 100 | 3.375 |
| 10:44 ET | 300 | 3.38 |
| 10:46 ET | 300 | 3.375 |
| 10:48 ET | 1300 | 3.375 |
| 10:50 ET | 400 | 3.395 |
| 10:51 ET | 500 | 3.3958 |
| 10:53 ET | 2230 | 3.39 |
| 10:55 ET | 600 | 3.4 |
| 10:57 ET | 1332 | 3.39 |
| 11:02 ET | 3397 | 3.39 |
| 11:04 ET | 200 | 3.395 |
| 11:06 ET | 471 | 3.4 |
| 11:08 ET | 882 | 3.405 |
| 11:09 ET | 100 | 3.4 |
| 11:13 ET | 649 | 3.385 |
| 11:15 ET | 8403 | 3.405 |
| 11:18 ET | 1000 | 3.41 |
| 11:22 ET | 100 | 3.405 |
| 11:26 ET | 200 | 3.405 |
| 11:27 ET | 600 | 3.4 |
| 11:29 ET | 859 | 3.4 |
| 11:31 ET | 586 | 3.385 |
| 11:36 ET | 100 | 3.38 |
| 11:38 ET | 977 | 3.38 |
| 11:40 ET | 1997 | 3.37 |
| 11:42 ET | 362 | 3.37 |
| 11:44 ET | 400 | 3.36 |
| 11:45 ET | 200 | 3.35 |
| 11:51 ET | 5463 | 3.39 |
| 11:54 ET | 500 | 3.395 |
| 11:56 ET | 1094 | 3.39 |
| 11:58 ET | 205 | 3.39 |
| 12:00 ET | 1303 | 3.39 |
| 12:02 ET | 345 | 3.405 |
| 12:03 ET | 756 | 3.41 |
| 12:05 ET | 3470 | 3.4 |
| 12:07 ET | 478 | 3.38 |
| 12:09 ET | 300 | 3.38 |
| 12:14 ET | 100 | 3.38 |
| 12:20 ET | 200 | 3.385 |
| 12:21 ET | 1400 | 3.385 |
| 12:23 ET | 200 | 3.385 |
| 12:25 ET | 100 | 3.38 |
| 12:27 ET | 200 | 3.3801 |
| 12:30 ET | 300 | 3.38 |
| 12:34 ET | 1142 | 3.38 |
| 12:36 ET | 500 | 3.37 |
| 12:38 ET | 400 | 3.385 |
| 12:39 ET | 300 | 3.38 |
| 12:41 ET | 200 | 3.38 |
| 12:45 ET | 758 | 3.38 |
| 12:48 ET | 300 | 3.375 |
| 12:50 ET | 400 | 3.375 |
| 12:52 ET | 1151 | 3.36 |
| 12:54 ET | 100 | 3.36 |
| 12:56 ET | 100 | 3.36 |
| 12:59 ET | 1397 | 3.365 |
| 01:01 ET | 400 | 3.37 |
| 01:03 ET | 550 | 3.385 |
| 01:06 ET | 2250 | 3.38 |
| 01:08 ET | 1300 | 3.3803 |
| 01:10 ET | 810 | 3.39 |
| 01:12 ET | 1618 | 3.385 |
| 01:14 ET | 400 | 3.385 |
| 01:15 ET | 770 | 3.38 |
| 01:17 ET | 2222 | 3.36 |
| 01:19 ET | 364 | 3.35 |
| 01:21 ET | 393 | 3.35 |
| 01:26 ET | 472 | 3.34 |
| 01:30 ET | 500 | 3.35 |
| 01:32 ET | 100 | 3.355 |
| 01:37 ET | 791 | 3.35 |
| 01:39 ET | 200 | 3.345 |
| 01:42 ET | 339 | 3.34 |
| 01:44 ET | 100 | 3.345 |
| 01:46 ET | 100 | 3.34 |
| 01:53 ET | 604 | 3.34 |
| 01:55 ET | 200 | 3.335 |
| 02:02 ET | 100 | 3.33 |
| 02:04 ET | 735 | 3.32 |
| 02:06 ET | 303 | 3.32 |
| 02:09 ET | 1137 | 3.3 |
| 02:11 ET | 2004 | 3.3 |
| 02:18 ET | 300 | 3.315 |
| 02:20 ET | 250 | 3.3199 |
| 02:22 ET | 200 | 3.315 |
| 02:24 ET | 3850 | 3.32 |
| 02:26 ET | 400 | 3.315 |
| 02:27 ET | 100 | 3.32 |
| 02:29 ET | 1058 | 3.3 |
| 02:31 ET | 200 | 3.3 |
| 02:33 ET | 882 | 3.295 |
| 02:36 ET | 100 | 3.295 |
| 02:38 ET | 1000 | 3.2993 |
| 02:42 ET | 221 | 3.3 |
| 02:45 ET | 300 | 3.3 |
| 02:47 ET | 400 | 3.3 |
| 02:51 ET | 1583 | 3.29 |
| 02:54 ET | 600 | 3.29 |
| 02:56 ET | 100 | 3.29 |
| 03:00 ET | 200 | 3.295 |
| 03:02 ET | 222 | 3.29 |
| 03:03 ET | 500 | 3.29 |
| 03:05 ET | 2784 | 3.285 |
| 03:07 ET | 900 | 3.28 |
| 03:09 ET | 1400 | 3.28 |
| 03:12 ET | 1000 | 3.285 |
| 03:14 ET | 1213 | 3.285 |
| 03:16 ET | 6118 | 3.2699 |
| 03:18 ET | 3265 | 3.265 |
| 03:20 ET | 7154 | 3.24 |
| 03:21 ET | 2294 | 3.24 |
| 03:23 ET | 6789 | 3.215 |
| 03:25 ET | 9358 | 3.225 |
| 03:27 ET | 4294 | 3.245 |
| 03:32 ET | 500 | 3.245 |
| 03:34 ET | 1200 | 3.2451 |
| 03:36 ET | 679 | 3.245 |
| 03:38 ET | 6338 | 3.23 |
| 03:39 ET | 1200 | 3.225 |
| 03:41 ET | 11042 | 3.215 |
| 03:43 ET | 5102 | 3.2 |
| 03:45 ET | 1200 | 3.2 |
| 03:48 ET | 3939 | 3.205 |
| 03:50 ET | 22849 | 3.225 |
| 03:52 ET | 5185 | 3.215 |
| 03:54 ET | 788 | 3.215 |
| 03:56 ET | 2352 | 3.215 |
| 03:57 ET | 15013 | 3.22 |
| 03:59 ET | 47072 | 3.21 |
Apr 2, 2024
DJ Omeros Shares Down 6% on Swing to 4Q Loss, from 11:07AM ET on Tuesday Apr 02, 2024 by Dow Jones
11:07AM ET on Tuesday Apr 02, 2024 by Dow Jones
Apr 1, 2024
Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results, from 4:02PM ET on Monday Apr 01, 2024 by Dow Jones
4:02PM ET on Monday Apr 01, 2024 by Dow Jones*DJ Omeros 4Q Loss/Shr 15c >OMER, from 4:02PM ET on Monday Apr 01, 2024 by Dow Jones
4:02PM ET on Monday Apr 01, 2024 by Dow Jones
Mar 27, 2024
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024, from 8:30AM ET on Wednesday Mar 27, 2024 by Dow Jones
8:30AM ET on Wednesday Mar 27, 2024 by Dow JonesPress Release: Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024, from 8:30AM ET on Wednesday Mar 27, 2024 by Dow Jones
8:30AM ET on Wednesday Mar 27, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Omeros Corp | 193.5M | -1.2x | --- |
Outlook Therapeutics Inc | 192.0M | -2.1x | --- |
Kodiak Sciences Inc | 189.0M | -0.7x | --- |
Adicet Bio Inc | 186.5M | -0.6x | --- |
X4 Pharmaceuticals Inc | 200.7M | -2.0x | --- |
Elevation Oncology Inc | 201.4M | -2.6x | --- |
Company Information
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Contact Information
- Headquarters
- 201 Elliott Avenue WestSEATTLE, WA, United States 98119
- Phone
- 206-676-5000
- Fax
- 206-676-5005
Executives
- Chairman of the Board, President, Chief Executive Officer
- Gregory Demopulos
- Chief Accounting Officer, Vice President - Finance
- Michael Jacobsen
- Vice President - Science, Chief Scientific Officer
- George Gaitanaris
- Vice President, General Counsel, Secretary
- Peter Cancelmo
- Vice President - Human Resources
- Peter Williams
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $193.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 57.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.32 |
EPS | $-2.79 |
Book Value | $-0.41 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
